Evidence map›Paper›PMID 41746285›Full record

ArticleJournal of the National Cancer Institute2026

Leveraging the national cancer institute's collaborative efforts to understand the benefits and harms of cannabis use among individuals with cancer.

Shannon M Nugent, Rebecca L Ashare, Jennifer Cullen, Reina Haque, Jennifer Hu, Richard T Lee, Salimah H Meghani, Arnold L Potosky, Beth A Reboussin, Alfonso Romero-Sandoval and 5 more

Abstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shannon M NugentKnight Cancer Institute Department of Psychology, Oregon Health and Science University.
Rebecca L AshareState University of New York at Buffalo, Buffalo, NY, USA.
Jennifer CullenHouston Methodist Neal Cancer Center, Houston, TX, USA.
Reina HaqueDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Jennifer HuDepartment of Public Health Sciences and Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, USA.
Richard T LeeDepartments of Supportive Care Medicine, City of Hope National Medical Center, Duarte, CA, USA.
Salimah H MeghaniDepartment of Biobehavioral Health Sciences, University of Pennsylvania, Philadelphia, PA, USA.
Arnold L PotoskyCancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Beth A ReboussinDivision of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC.
Alfonso Romero-SandovalDivision of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC.
Kimberly G WagonerDivision of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC.
Yan WangDepartment of Epidemiology, University of Florida, Gainesville, FL, USA.
Brooke WorsterSydney Kimmel Cancer Center, Thomas Jefferson University.
Kelly K FilipskiClinical and Translational Epidemiology Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, NIH.
Andrew N FreedmanClinical and Translational Epidemiology Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, NIH.

Funding

Collaborations and NCORP Collective ManagementUG1CA189823 · NCI · MAYO CLINIC ROCHESTER · PI Evanthia Galanis, Olwen Hahn · 2014 to 2026
$120.6M
Wake Forest NCORP Research BaseUG1CA189824 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Emily Van Meter Dressler, GLENN J LESSER · 2014 to 2026
$57.9M
Longitudinal assessment of benefits and harms of cannabis use among community-based cancer patients during initial cancer treatmentU01CA286821 · NCI · GEORGETOWN UNIVERSITY · PI HAQUE, REINA, POTOSKY, ARNOLD L · 2023 to 2025
$3.3M
Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology ClinicsU01CA286813 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BETH A. REBOUSSIN, E. Alfonso Romero-Sandoval · 2023 to 2026
$2.6M
Assessing benefits and harms of cannabis use in patients treated with immunotherapy for cancer: a prospective cohort studyU01CA286811 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Rebecca Ashare, Salimah H. Meghani · 2023 to 2026
$2.5M
Assessing Benefits and Harms of Medical Cannabis and Cannabinoid Use in Breast Cancer Patients During and After TreatmentsU01CA286810 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Jennifer J Hu, Yan Wang · 2023 to 2026
$2.1M
A Prospective Cohort Study of Patients with Non-Small Cell Lung Cancer and Multiple Myeloma to Assess the Benefits and Harms Related to Cannabis Use During TreatmentU01CA286808 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Jennifer Cullen, Richard T Lee · 2023 to 2026
$1.8M
NCI NIH HHS U01 CA286808NCI NIH HHS U01 CA286810NCI NIH HHS U01 CA286811NCI NIH HHS U01 CA286813NCI NIH HHS U01 CA286821NCI NIH HHS UG1 CA189823NCI NIH HHS UG1 CA189824
6 · The paper itself

Abstract

Cannabis use for symptom management among patients with cancer has increased significantly in recent years, with many reporting benefits for pain, anxiety, sleep, nausea, appetite as well as other symptoms. However, rigorous prospective data on the potential benefits and harms of cannabis use in this population are lacking. This Commentary describes a United States National Cancer Institute (NCI)-led initiative addressing this research gap by supporting five prospective observational studies evaluating the benefits and harms of cannabis use among a large, heterogeneous samples of patients with cancer undergoing active systemic treatment. We provide an overview of each study, including cancer type, treatment modalities, inclusion/exclusion criteria, data collection methods, and both patient-reported and cancer-related outcomes.

Indexed as

cancercannabismarijuanasymptom management

Identifiers

PMID41746285
PMCPMC13384249

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.